Skip to main content
TipRanks
Go Ultimate75% OFF

Spero Therapeutics (SPRO) AI Stock Analysis

605 Followers
SPRO

Spero Therapeutics

(NASDAQ:SPRO)

Select Model
Rating:47Neutral
Price Target:$0.86â–²(4.24% Upside)
Action:reiterated
Date:11/14/26

The score is held down primarily by weak financial performance (ongoing cash burn, volatile revenue/earnings, and a deteriorated TTM equity/leverage profile) and bearish technicals (below key moving averages with negative MACD). These are partially offset by a stronger earnings-call outlook driven by non-dilutive financing that extends runway to 2H 2029 and key strategic milestones (Utebzi approval and the SP001 license), though execution and funding-repayment dependence remain notable risks.

Positive Factors
Approved Product and Commercial PartnerUtebzi approval creates a validated commercial asset in a serious-infection market, while GSK’s exclusive commercialization role provides an established partner for launch execution. This can support recurring milestone and royalty opportunities without requiring Spero to build a full U.S. sales infrastructure.
Negative Factors
Persistent Cash BurnPersistent negative cash generation means Spero is not currently funding operations from internally generated cash. Continued burn can consume financing proceeds faster than planned and may ultimately require additional capital, creating funding uncertainty and potential dilution even with the extended runway.

Spero Therapeutics (SPRO) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%40%SPRO-65.29%SPY+9.80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$50.92M
Dividend Yield
―
Average Volume (3M)
529.78K
Price to Earnings (P/E)
-1.8
Beta (1Y)
1.71
Revenue Growth
36.15%
EPS Growth
38.57%
Country
US
Employees
25
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Spero Therapeutics Business Overview & Revenue Model

Company Description

Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases withi...

Spero Therapeutics Earnings Call Summary

Earnings Call Date:Aug 12, 2026(Q2-2026)|% Change Since:-30.59%|Next Earnings Date:May 16, 2022
Earnings Call SentimentPositive

The call conveyed a strategic positive shift: an important product approval (Utebzi), a high-value in-license (SP001) with a clear development plan in IgG4-RD, a non-dilutive $105M financing that extends runway into H2 2029, and a strengthened clinical leadership team. Offsetting these positives are an absence of current revenue (Q2 2026 revenue $0 vs $14.2M prior year), a wider net loss and increased loss per share, dependence on GSK royalty/milestone streams to service the financing, and SP001 remaining early-stage with a small planned Phase II. On balance, management’s actions materially de-risk near-term funding and position the company for an immunology strategy, but meaningful clinical and commercial execution risks remain.

Positive Updates

FDA Approval of Utebzi (tebipenem pivoxil)
On June 17, 2026 the FDA approved Utebzi, the first and only oral carbapenem for complicated urinary tract infections (including pyelonephritis). Approval based on PIVOT-PO Phase III (stopped early for efficacy May 2025). GSK holds exclusive commercialization rights (excludes certain Asian territories where Meiji retains rights) and expects U.S. availability in the second half of 2026.

Negative Updates

No Revenue in Q2 2026 Versus Prior-Year Collaboration Revenue
Total revenue was $0 in Q2 2026 compared with $14.2 million in Q2 2025 (a decline of $14.2M or 100%), primarily because prior-period collaboration revenue from Pfizer and GSK and government awards were fully realized in prior periods.

Company Guidance

Spero said the key near‑term financial and development guidance is anchored by a $105.0M nondilutive, nonrecourse royalty financing (special‑purpose subsidiary issued $105M senior secured notes, 10% annual interest, 9‑year maturity, principal & interest payable quarterly from GSK Utebzi milestones/royalties; after repayment Spero retains 35% of additional GSK proceeds) and an exclusive SP001 license with Innovent with an estimated $1.1B total contingent value; cash & cash equivalents were $50.8M as of June 30 (pre‑financing) and, together with the financing, are expected to fund the $35M nonrefundable Innovent upfront plus operating and capex into the second half of 2029 (cash runway updated to 2H‑2029). Operational milestones include a Phase II IgG4‑RD trial planned to begin in Q2‑2027 (open‑label, 6 monthly doses, two dosing arms, up to ~15 patients per arm, i.e., ~30 patients total) and Utebzi availability in the U.S. in 2H‑2026; reported Q2‑2026 P&L metrics were net loss $9.6M (diluted loss per share $0.16) vs $1.7M ($0.03) in Q2‑2025, revenue $0 (vs $14.2M), R&D $3.4M (vs $10.7M) and G&A $6.5M (vs $5.9M).

Spero Therapeutics Financial Statement Overview

Summary

Financials are constrained by persistent cash burn and unstable profitability. Income results are volatile with a sharp TTM revenue decline and a sizable TTM net loss with very negative margins, while cash flow is consistently negative (TTM FCF about -$40.4M). Balance sheet risk increased in the TTM snapshot with sharply thinner equity and much higher debt-to-equity versus prior years.

Income Statement

41Neutral

Balance Sheet

56Neutral

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Mar 2022
Income Statement
Total Revenue39.92M59.62M47.98M103.78M48.58M3.07M
Gross Profit39.92M59.62M-48.78M52.34M48.58M3.07M
EBITDA8.11M8.83M-72.48M27.15M-42.94M-87.17M
Net Income-29.51M8.57M-68.57M22.81M-46.41M-89.76M
Balance Sheet
Total Assets110.03M68.92M110.54M182.39M124.80M171.07M
Cash, Cash Equivalents and Short-Term Investments107.93M40.27M52.89M76.33M109.11M146.40M
Total Debt1.59M2.90M4.30M5.54M6.65M7.33M
Total Liabilities109.25M9.90M64.42M75.50M48.87M82.78M
Stockholders Equity781.00K59.02M46.12M106.89M75.93M88.29M
Cash Flow
Free Cash Flow-40.45M-12.62M-23.44M-32.99M-7.73M-64.35M
Operating Cash Flow-40.45M-12.62M-23.44M-32.99M-7.73M-64.35M
Investing Cash Flow000033.81M7.67M
Financing Cash Flow99.76M00221.00K-29.55M84.05M

Spero Therapeutics Technical Analysis

Technical Analysis SentimentNegative
Last Price0.83

Price Trends

50DMA1.11Negative
100DMA1.26Negative
200DMA1.89Negative

Market Momentum

MACD-0.07Positive
RSI27.03Positive
STOCH5.80Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SPRO, the sentiment is Negative. The current price of 0.83 is below the 20-day moving average (MA) of 1.03, below the 50-day MA of 1.11, and below the 200-day MA of 1.89, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 27.03 is Positive, neither overbought nor oversold. The STOCH value of 5.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SPRO.

Spero Therapeutics Risk Analysis

Spero Therapeutics disclosed 65 risk factors in its most recent earnings report. Spero Therapeutics reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Our ability to realize the value of Utebzi depends on commercialization efforts through our partnership with GSK.Q3, 2026
2.We are substantially dependent on the success of our new product candidate, SP001, and our focus on SP001 may not be successful.Q3, 2026
3.As part of our milestone and royalty financing transaction with HCRx, we transferred the GSK License Agreement and our rights thereunder, along with related intellectual property, to one of two newly formed special purpose subsidiaries of ours, and provided HCRx with a right of first recourse to such assets to satisfy our obligations to HCRx. As a result, if we are unable to satisfy our obligations under the milestone and royalty financing transaction, we could lose all retained rights to future milestone and royalty payments from HCRx and related assets, which could have a material adverse effect on our business, financial condition and stock price.Q3, 2026

Spero Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SPRO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
INOINO55Neutral$305.31M-2.12-9999.00%―63.93%68.94%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SPROSPRO47Neutral$50.92M-1.78-75.22%―36.15%38.57%
MCRBMCRB44Neutral$14.68M-0.29-148.34%―505.41%-889.29%
PDSBPDSB44Neutral$82.33M-1.40-559.99%――32.24%
COCPCOCP43Neutral$18.82M-1.21-320.01%――17.71%
NNVCNNVC36Underperform$30.41M-2.19-137.90%――-5.19%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%SPROINONNVCMCRBPDSBCOCPDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SPRO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SPROSpero Therapeutics0.83-1.48-64.24%
INOInovio Pharmaceuticals1.71-0.05-2.84%
NNVCNanoViricides Inc1.17-0.10-7.87%
MCRBSeres Therapeutics Inc.1.33-16.38-92.49%
PDSBPds Biotechnology0.810.056.89%
COCPCocrystal Pharma0.970.077.55%

Spero Therapeutics Corporate Events

Executive/Board Changes

Spero Therapeutics Appoints William Ho to Board

Neutral
Nov 10, 2026

On November 9, 2026, Patrick Vink notified Spero Therapeutics’ board that he would resign as a Class II director and from committee and subsidiary-director roles, effective November 10. The company said the resignation was not due to any dispute or d...

Business Operations and StrategyExecutive/Board Changes

Spero Therapeutics announces planned COO retirement and transition

Neutral
Oct 27, 2026

On October 26, 2026, Spero Therapeutics, Inc. announced that Chief Operating Officer Timothy Keutzer will retire from the company effective December 31, 2026, concluding an 11-year tenure marked by leadership and significant contributions. To support...

Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance

Spero Therapeutics Launches New Jefferies ATM Equity Program

Neutral
Aug 28, 2026

On August 28, 2026, Spero Therapeutics, Inc. entered into a new Open Market Sale Agreement with Jefferies LLC, allowing the company, once its pending universal shelf registration statement becomes effective, to sell up to $100 million of common stock...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026